Novel preparation of enteric-coated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 68, Issue 2, 2008, Pages 260-266

  Oosegi, Tomoko ^a   Onishi, Hiraku ^a   Machida, Yoshiharu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Chitosan prednisolone conjugate microspheres; Drug release; Eudragit coated microparticles; Morphological change; Particle characteristics; Specific delivery

Indexed keywords

CHITOSAN; CHITOSAN SUCCINYL PREDNISOLONE CONJUGATE; EUDRAGIT; MICROSPHERE; PREDNISOLONE; UNCLASSIFIED DRUG;

ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED DRUG RELEASE; DRUG COATING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; IN VITRO STUDY; PH; SCANNING ELECTRON MICROSCOPY;

CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLON; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PREDNISOLONE; TABLETS, ENTERIC-COATED;

EID: 37849008649     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.06.016     Document Type: Article

References (14)

1. Gionchetti P., Rizzello F., Habal F., Morselli C., Amadini C., Romagnoli R., and Campieri M. Standard treatment of ulcerative colitis. Dig. Dis. 21 (2003) 157-167
2. Campieri M., Ferguson A., Doe W., Persson T., and Nilsson L.G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 41 (1997) 209-214
3. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokinet. 10 (1985) 285-302
4. Larouche J., Morais J., Picard M., Lambert C., Spenard J., Landriault H., Kennedy G., and Poitras P. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Aliment. Pharmacol. Ther. 9 (1995) 315-320
5. Tozaki H., Odoriba T., Okada N., Fujita T., Terabe A., Suzuki T., Okabe S., Muranishi S., and Yamamoto A. Chitosan capsules for colon-specific drug deliver: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J. Control. Release 82 (2002) 51-61
6. Tabata Y., Inoue Y., and Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 14 (1996) 1677-1685
7. Lamprecht A., Schafer U., and Lehr C.M. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 18 (2001) 788-793
8. Lamprecht A., Ubrich N., Yamamoto H., Schafer U., Takeuchi H., Maincent P., Kawashima Y., and Lehr C.M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299 (2001) 775-781
9. Nakase H., Okazaki K., Tabata Y., Uose S., Ohana M., Uchida K., Matsushima Y., Kawanami C., Oshima C., Ikada Y., and Chiba T. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther. 292 (2000) 15-21
10. Hejazi R., and Amiji M. Chitosan-based gastrointestinal delivery systems. J. Control. Release 89 (2003) 151-165
11. Onishi H., Oosegi T., Machida Y., and McGinity J.W. Preparation and in vitro evaluation of chitosan microspheres containing prednisolone: comparison of simple and conjugate microspheres. Drug Dev. Ind. Pharm. 31 (2005) 597-605
12. H. Onishi, T. Oosegi, J.W. McGinity, Y. Machida, Eudragit coating of chitosan-prednisolone conjugate microspheres and in vitro evaluation of coated microspheres, Drug Dev. Ind. Pharm., in press.
13. Li J., Revol J.F., and Marchessault R.H. Rheological properties of aqueous suspensions of chitin crystallites. J. Colloid. Interface Sci. 183 (1996) 365-373
14. Khan M.Z., Stedul H.P., and Kurjakovic N. A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations. Drug Dev. Ind. Pharm. 26 (2000) 549-554